[go: up one dir, main page]

WO2020216383A1 - Anticorps anti-lag -3 - Google Patents

Anticorps anti-lag -3 Download PDF

Info

Publication number
WO2020216383A1
WO2020216383A1 PCT/CN2020/087141 CN2020087141W WO2020216383A1 WO 2020216383 A1 WO2020216383 A1 WO 2020216383A1 CN 2020087141 W CN2020087141 W CN 2020087141W WO 2020216383 A1 WO2020216383 A1 WO 2020216383A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
amino acid
acid sequence
variable domain
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2020/087141
Other languages
English (en)
Inventor
Leyan TANG
Allison SCHULKINS
Kimberly THAN
Chun-Nan Chen
Jingyun MIAO
Xiaohui Zhang
Xiaojuan Shi
Lin Zhang
Pingju GE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acrobiosystems Inc
Single Cell Technology Inc
Original Assignee
Acrobiosystems Inc
Single Cell Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acrobiosystems Inc, Single Cell Technology Inc filed Critical Acrobiosystems Inc
Publication of WO2020216383A1 publication Critical patent/WO2020216383A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • Lymphocyte Activation Gene-3 is a member of the immunoglobulin supergene family, and is expressed on activated T cells (Huard et al., 1994a) , NK cells (Triebel et al., 1990) , regulatory T cells (Huang et al., 2004; Camisaschi et al., 2010; Gagliani et al., 2013) , and plasmacytoid dendritic cells (DCs) (Workman et al., 2009) .
  • LAG-3 is a membrane protein encoded by a gene located on chromosome 12 and is structurally and genetically related to CD4.
  • LAG-3 can interact with MHC class II molecules on the cell surface (Baixeras et al., 1992; Huard et al., 1996) . It has been suggested that the direct binding of LAG-3 to MHC class II plays a role in down-regulating antigen-dependent stimulation of CD4+T lymphocytes (Huard et al., 1994b) and LAG-3 blockade has also been shown to reinvigorate CD8+ lymphocytes in both tumor or self-antigen (Grosso et al., 2007; Blackburn et al., 2009) .
  • LAG-3 intra-cytoplasmic region of LAG-3 can interact with LAP (LAG-3-associated protein) , which is a signal transduction molecule involved in the downregulation of the CD3/TCR activation pathway (Iouzalen et al., 2001) .
  • LAP LAG-3-associated protein
  • CD4+CD25+ regulatory T cells have been shown to express LAG-3 upon activation, which contributes to the suppressor activity of Treg cells (Huang et al., 2004) .
  • LAG-3 can also negatively regulate T cell homeostasis by Treg cells in both T cell-dependent and independent mechanisms (Workman and Vignali, 2005) .
  • the anti-LAG-3 antibody molecules disclosed herein can be used to treat, prevent and/or diagnose cancerous or malignant disorders (e.g., cancers such melanoma, e.g., advanced stage melanoma; pancreatic cancer, e.g., advanced pancreatic cancer; solid tumors; breast cancer, e.g., metastatic breast carcinoma; renal cell carcinoma, e.g., advanced or metastatic renal cell carcinoma (MRCC) or clear cell renal cell carcinoma) , as well as potentially infectious diseases (e.g., hepatitis, e.g., hepatitis B; influenza) .
  • cancers such melanoma, e.g., advanced stage melanoma
  • pancreatic cancer e.g., advanced pancreatic cancer
  • solid tumors breast cancer, e.g., metastatic breast carcinoma
  • renal cell carcinoma e.g., advanced or metastatic renal cell carcinoma (MRCC) or clear cell renal cell carcinoma
  • infectious diseases e.g.,
  • SCT-Ca20 mature heavy chain variable domain protein sequence 20 SCT-Ca21 mature heavy chain variable domain protein sequence 21 SCT-Ca22 mature heavy chain variable domain protein sequence 22 SCT-Ca23 mature heavy chain variable domain protein sequence 23 SCT-Ca24 mature heavy chain variable domain protein sequence 23 SCT-Ca25 mature heavy chain variable domain protein sequence 24 SCT-Ca26 mature heavy chain variable domain protein sequence 25 SCT-Ca27 mature heavy chain variable domain protein sequence 26 SCT-Ca28 mature heavy chain variable domain protein sequence 27 SCT-Ca29 mature heavy chain variable domain protein sequence 28 SCT-Ca30 mature heavy chain variable domain protein sequence 29 SCT-Ca31 mature heavy chain variable domain protein sequence 29 SCT-Ca32 mature heavy chain variable domain protein sequence 30 SCT-Ca33 mature heavy chain variable domain protein sequence 31 SCT-Ca34 mature heavy chain variable domain protein sequence 32 SCT-Ca35 mature heavy chain variable domain protein sequence 33 SCT-Ca36 mature heavy chain variable domain protein sequence 34 SCT-Ca37 mature heavy chain variable domain protein sequence 35 SCT
  • SCT-Ca61 mature heavy chain variable domain protein sequence 59 SCT-Ca62 mature heavy chain variable domain protein sequence 59 SCT-Ca63 mature heavy chain variable domain protein sequence 60 SCT-Ca64 mature heavy chain variable domain protein sequence 61 SCT-Ca65 mature heavy chain variable domain protein sequence 62 SCT-Ca66 mature heavy chain variable domain protein sequence 63 SCT-Ca67 mature heavy chain variable domain protein sequence 64 SCT-Ca68 mature heavy chain variable domain protein sequence 65 SCT-Ca69 mature heavy chain variable domain protein sequence 66 SCT-Ca70 mature heavy chain variable domain protein sequence 67 SCT-Ca01 mature light chain variable domain protein sequence 68 SCT-Ca02 mature light chain variable domain protein sequence 69 SCT-Ca03 mature light chain variable domain protein sequence 70 SCT-Ca04 mature light chain variable domain protein sequence 71 SCT-Ca05 mature light chain variable domain protein sequence 72 SCT-Ca06 mature light chain variable domain protein sequence 73 SCT-Ca07 mature light chain variable domain protein sequence 74 SCT-C
  • SCT-Ca32 mature light chain variable domain protein sequence 93 SCT-Ca33 mature light chain variable domain protein sequence 94 SCT-Ca34 mature light chain variable domain protein sequence 95 SCT-Ca35 mature light chain variable domain protein sequence 96 SCT-Ca36 mature light chain variable domain protein sequence 97 SCT-Ca37 mature light chain variable domain protein sequence 98 SCT-Ca38 mature light chain variable domain protein sequence 99 SCT-Ca39 mature light chain variable domain protein sequence 100 SCT-Ca40 mature light chain variable domain protein sequence 101 SCT-Ca41 mature light chain variable domain protein sequence 102 SCT-Ca42 mature light chain variable domain protein sequence 103 SCT-Ca43 mature light chain variable domain protein sequence 103 SCT-Ca44 mature light chain variable domain protein sequence 103 SCT-Ca45 mature light chain variable domain protein sequence 104 SCT-Ca46 mature light chain variable domain protein sequence 105 SCT-Ca47 mature light chain variable domain protein sequence 106 SCT-Ca48 mature light chain variable domain protein sequence 107 SCT
  • FIG. 1. shows dose-dependent blockade of anti-human LAG-3 antibody interfering the interaction between LAG-3 and its ligand FGL1 with LAG-3 coated on ELISA plates.
  • FIG. 2. shows dose-dependent blockade of anti-human LAG-3 antibody interfering the interaction between LAG-3 and its ligand FGL1 with FGL1 coated on ELISA plates.
  • FIG. 3. shows interaction analysis of human LAG-3 with anti-LAG-3 antibody (SCT-Ca01) in a surface plasmon resonance assay on Biacore T200.
  • the disclosure provides antibodies that bind to LAG-3.
  • the disclosure provides an isolated antibody that binds to SEQ ID NO: 1.
  • the disclosure provides antibodies that bind specifically to SEQ ID NO: 1.
  • the term “antibody” as used herein includes both full-length immunoglobulins and antibody fragments that bind to LAG-3.
  • the antibodies can be, e.g., a monoclonal, polyclonal, chimeric, humanized, or single chain antibody.
  • the terms “antigen binding fragment, ” “fragment, ” and “antibody fragment” are used interchangeably to refer to any fragment that comprises a portion of a full-length antibody, generally at least the antigen binding portion or the variable region thereof.
  • Examples of antibody fragments include, but are not limited to, diabodies, single-chain antibody molecules, multi-specific antibodies, Fab, Fab’, F (ab') 2, Fv or scFv.
  • terapéuticaally effective is intended to qualify the amount of active ingredients used in the treatment of a disease or disorder or on the effecting of a clinical endpoint.
  • terapéuticaally acceptable refers to those compounds (or salts, prodrugs, tautomers, zwitterionic forms, etc. ) which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
  • treating, ” “treatment, ” and the like, as used herein, mean ameliorating a disease, so as to reduce, ameliorate, or eliminate its cause, its progression, its severity, or one or more of its symptoms, or otherwise beneficially alter the disease in a subject.
  • Reference to “treating, ” or “treatment” of a patient is intended to include prophylaxis.
  • Treatment may also be preemptive in nature, i.e., it may include prevention of disease in a subject exposed to or at risk for the disease. Prevention of a disease may involve complete protection from disease, for example as in the case of prevention of infection with a pathogen or may involve prevention of disease progression.
  • prevention of a disease may not mean complete foreclosure of any effect related to the diseases at any level, but instead may mean prevention of the symptoms of a disease to a clinically significant or detectable level. Prevention of diseases may also mean prevention of progression of a disease to a later stage of the disease.
  • subject and “patient” are used interchangeably herein to mean all mammals including humans. Examples of subjects include, but are not limited to, humans, monkeys, dogs, cats, horses, cows, goats, sheep, pigs, and rabbits. In one embodiment, the subject or patient is a human.
  • the cancer treated with the anti-LAG-3 antibody molecule includes but is not limited to, a solid tumor, a hematological cancer (e.g., leukemia, lymphoma, myeloma) , and a metastatic lesion thereof.
  • the cancer is a solid tumor.
  • solid tumors include malignancies, e.g., sarcomas and carcinomas (e.g., adenocarcinomas) , of the various organ systems, such as those affecting lung, breast, lymphoid, gastrointestinal or colorectal, genitals and genitourinary tract (e.g., renal, urothelial, bladder cells) , pharynx, CNS (e.g., brain, neural or glial cells) , skin (e.g., melanoma) , head and neck (e.g., head and neck squamous cell carcinoma (HNCC) ) , and pancreas.
  • malignancies e.g., sarcomas and carcinomas (e.g., adenocarcinomas)
  • carcinomas e.g., adenocarcinomas
  • the various organ systems such as those affecting lung, breast, lymphoid, gastrointestinal or colorectal, genital
  • melanoma colon cancers, gastric cancer, rectal cancer, renal-cell carcinoma, breast cancer (e.g., a breast cancer that does not express one, two or all of estrogen receptor, progesterone receptor, or Her2/neu, e.g., a triple negative breast cancer) , liver cancer, a lung cancer (e.g., a non-small cell lung cancer (NSCLC) (e.g., a NSCLC with squamous and/or non-squamous histology) or small cell lung cancer) , prostate cancer, cancer of head or neck (e.g., HPV+ squamous cell carcinoma) , cancer of the small intestine and cancer of the esophagus.
  • NSCLC non-small cell lung cancer
  • head or neck e.g., HPV+ squamous cell carcinoma
  • hematological cancer examples include, but is not limited to, leukemia (e.g., a myeloid leukemia, lymphoid leukemia, or chronic lymphocytic leukemia (CLL) ) , lymphoma (e.g., Hogdkin lymphoma (HL) , non-Hogdkin lymphoma (NHL) , Diffuse large B-cell lymphoma (DLBCL) , T-cell lymphoma, or mantle cell lymphoma (MCL) ) , and myeloma, e.g., multiple myeloma.
  • the cancer may be at an early, intermediate, late stage or metastatic cancer.
  • LAG-3 generally known in the art, please see U.S. Pat. No. 9,207,238, which is incorporated in its entirety by reference.
  • the provided antibodies may be used to diagnose, treat, or monitor LAG-3-expressing cancer and its progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with LAG-3-expressing cancer and thus may be amenable to treatment with a LAG-3-specific anti-cancer therapeutic.
  • the antibodies or fragments thereof described herein may be used for various in vitro molecular-biology applications such as, for example, enzyme-linked immunosorbent assays (ELISA) , Western blots, immunohistochemistry, immunocytochemistry, flow cytometry and fluorescence-activated cell sorting (FACS) , immunoprecipitation, and/or enzyme-linked immunospot assays (ELISPOT) .
  • ELISA enzyme-linked immunosorbent assays
  • FACS fluorescence-activated cell sorting
  • ELISPOT enzyme-linked immunospot assays
  • the antibodies or fragments thereof may be packaged in kits with or without additional reagents known to those of skill in the art for practicing any of the molecular biology techniques disclosed above.
  • the disclosure provides the antibodies SCT-Ca01, SCT-Ca02, SCT-Ca03, SCT-Ca04, SCT-Ca05, SCT-Ca06, SCT-Ca07, SCT-Ca08, SCT-Ca09, SCT-Ca10, SCT-Ca11, SCT-Ca12, SCT-Ca13, SCT-Ca14, SCT-Ca15, SCT-Ca16, SCT-Ca17, SCT-Ca18, SCT-Ca19, SCT-Ca20, SCT-Ca21, SCT-Ca22, SCT-Ca23, SCT-Ca24, SCT-Ca25, SCT-Ca26, SCT-Ca27, SCT-Ca28, SCT-Ca29, SCT-Ca30, SCT-Ca31, SCT-Ca32, SCT-Ca33, SCT-Ca34, SCT-Ca35, SCT-C
  • recombinant anti-LAG-3 antibodies such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the disclosure.
  • Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques such as, for example, the methods described in U.S. Pat. No. 7,112,421; Better et al. (1988) Science 240: 1041-1043; or Liu et al. (1987) Proc. Natl. Acad. Sci. USA 84: 3439-3443.
  • Antibody Variable Domain Sequence such as, for example, the methods described in U.S. Pat. No. 7,112,421; Better et al. (1988) Science 240: 1041-1043; or Liu et al. (1987) Proc. Natl. Acad. Sci. USA 84: 3439-3443.
  • the antibodies of the disclosure may comprise the heavy chain variable domain sequences of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, S
  • the heavy chain variable domain sequences may consist essentially of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO
  • the antibodies of the disclosure may comprise the light chain variable domain sequences of SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO:
  • the light chain variable domain sequences may consist essentially of SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, S
  • variable domain sequence comprising a sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to a sequence selected from SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 31, S
  • variable domain sequence comprising a sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to a sequence selected from NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO:
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 4 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 67.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 4 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 68.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 5 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 69.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 6 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 70.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 7 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 71.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 8 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 72.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 9 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 73.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 9 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 74.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 10 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 75.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 11 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 76.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 12 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 77.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 12 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 78.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 13 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 79.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 14 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 80.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 15 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 81.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 16 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 79.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 17 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 82.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 18 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 82.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 18 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 83.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 19 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 84.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 20 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 85.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 21 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 82.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 22 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 82.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 23 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 82.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 23 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 84.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 24 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 86.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 25 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 87.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 26 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 88.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 27 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 89.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 28 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 90.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 29 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 91.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 29 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 92.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO: 30 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 93.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 31 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 94.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 32 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 95.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 33 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 96.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 34 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 97.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 35 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 98.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 36 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 99.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 37 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 100.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 38 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 101.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 39 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 102.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 40 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 103.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 41 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 103.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 42 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 103.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 43 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 104.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 44 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 105.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 45 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 106.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 46 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 107.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 47 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 108.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 48 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 109.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 49 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 110.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 50 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 111.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 51 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 112.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 52 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 113.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 53 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 114.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 54 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 115.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 55 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 115.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 56 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 116.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 57 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 117.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 58 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 118.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 59 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 119.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 59 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 120.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 60 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 121.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 61 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 122.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 62 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 123.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 63 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 124.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 64 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 125.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 65 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 117.
  • the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 66 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95%identical to SEQ ID NO: 113.
  • Table 1 provides a summary of the LAG-3-specific antibodies described herein:
  • compositions comprising the antibodies or antibody fragments of the present disclosure are also contemplated and can be used in the methods disclosed herein.
  • Pharmaceutical compositions can comprise one or more of the antibodies or antibody fragments described herein and a pharmaceutically acceptable carrier or excipient.
  • the carrier or excipient may facilitate administration, it should not itself induce the production of antibodies harmful to the subject or individual receiving the composition; nor should it be toxic.
  • Suitable carriers may be large, slowly metabolized macromolecules such as proteins, polypeptides, liposomes, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles, and are known to one of skill in the art.
  • the antibodies or an antigen binding fragments described herein, or the pharmaceutical compositions disclosed herein may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intraperitoneal, intrathecal, intraventricular, transdermal, transcutaneous, topical, subcutaneous, intranasal, enteral, sublingual, intravaginal or rectal routes.
  • the therapeutic compositions may be prepared as injectables, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared.
  • the antibody, or an antigen binding fragment thereof, or pharmaceutical composition is administered intravenously. In another embodiment, the antibody, or an antigen binding fragment thereof, or pharmaceutical composition is administered by intravenous infusion.
  • Direct delivery of the compositions will generally be accomplished by injection, subcutaneously, intraperitoneally, intravenously or intramuscularly, or delivered to the interstitial space of a tissue.
  • the compositions can also be administered into a lesion.
  • Dosage treatment may be a single dose schedule or a multiple dose schedule.
  • Known antibody-based pharmaceuticals provide guidance relating to frequency of administration e.g., whether a pharmaceutical should be delivered daily, weekly, monthly, etc. Frequency and dosage may also depend on the severity of symptoms.
  • the active ingredient in the composition will be an antibody molecule, an antibody fragment or variants and derivatives thereof. As such, it will be susceptible to degradation in the gastrointestinal tract. Thus, if the composition is to be administered by a route using the gastrointestinal tract, the composition will need to contain agents which protect the antibody from degradation, but which release the antibody once it has been absorbed from the gastrointestinal tract.
  • the methods of the present invention can use an antibody, or an antigen binding fragment thereof, as described above, alone or in combination with other pharmaceutically active compounds, to treat conditions such as those disclosed hereinabove.
  • the additional pharmaceutically active compound (s) can be administered simultaneously (either in the same dosage form or in separate dosage forms) or sequentially.
  • the present invention comprises methods for treating a condition by administering to the subject a therapeutically effective amount of an antibody, or an antigen binding fragment thereof, of the present invention and one or more additional pharmaceutically active compounds.
  • the antibody, or an antigen binding fragment thereof, of the present invention is used in combination with existing LAG-3-related disease therapies.
  • Example 1 Isolation of murine anti-human LAG-3 antibodies immunization, &single cell suspension generation
  • Recombinant human LAG-3 (huLAG-3-His tagged, catalog no: LA3-H5222, ACROBiosystems, Beijing, China, SEQ ID NO: 2) was used to immunize young C57/BL6 mice each with 80 ⁇ g of the protein in Sigma Adjuvant (Sigma-Aldrich, St. Louis, MO) over a period of 35 days using a rapid immunization protocol of Antibody Solutions (Sunnyvale, CA) .
  • the lymph nodes were harvested on day 35. Single cell suspension of the lymph node was generated, and the suspension was filtered through a 70 ⁇ m mesh (BD Bioscience) to remove clumps.
  • the filtered lymphocyte suspension was enriched for plasma cells actively secreting IgGs using a kit based on cell surface expression of CD138 (Miltenyi, Auburn, CA) .
  • a kit based on cell surface expression of CD138 Molyzed Cell Sorting Kit *Ultra Convenient*.
  • freshly enriched plasma cells were deposited on a PDMS device to allow a single cell settled in the microwells on the device.
  • Antibody secreted from each plasma cell was captured on a derivatized microscope slide.
  • Antigen-specific antibody secreting cells were identified by interrogating the antibody capture slide with varying concentrations of fluorescently labeled LAG-3 protein tagged with human Fc (ACROBiosystems, Beijing, China, catalog no: LA3-H5255, SEQ ID NO: 3) . Labeling was done using a kit (AnaSpec, Fremont, CA, AS-72046, AnaTag TM HiLyte TM Fluor 555 Microscale Protein Labeling Kit *Ultra Conveni
  • oligonucleotide microarray (Agilent, Santa Clara, CA) . This procedure was previously described in U.S. Patent No. 9,328,172.
  • the custom oligonucleotide microarray is prepared such that each feature contains not only a unique tag specifying its coordinate but also capture probes for all subclasses (1, 2a, 2b, and 3) of murine IgG heavy chain, murine Ig kappa light chain.
  • Captured mRNA on the custom microarray was further processed to synthesize cDNA of each mRNA incorporating the unique tag originally on each feature.
  • the cDNA is then amplify using a Taq polymerase (Promega, Madison, WI) and appropriate set of primers to allow amplification of the following genes: variable domain of IgG heavy chain subclasses and variable domain of Ig kappa light chain. Though now released from cells, these fragments of each gene are now labeled with the unique tag from the custom oligonucleotide microarray manifesting their originating locations.
  • the amplicons were further manipulated to have appropriate sequence attached at both ends to enable sequencing on an Illumina MiSeq instrument using 2 x 250 bp chemistry at SeqMatic LLC (Fremont, CA) .
  • V H or V L sequence containing the identified CDR3s was identified and the associated sequencing reads were assembled into full-length cDNA sequences for V H and V L .
  • the pair of full-length cDNA was correlated with the affinity measurements associated with each of the antigen-specific antibody spot.
  • a select subset of paired V H and V L anti-LAG-3 antibody sequences was used to synthesize corresponding gene fragments by a service provider according to the known art.
  • the resulting gene fragments were cloned into an appropriate plasmid vector and transfected into an appropriate mammalian host, such as HEK293, for recombinant expression to produce an antibody preparation in full-IgG format.
  • the antibody preparations were characterized by measurements at OD280 to assess the amount produced and by gel electrophoresis on PAGE to assess the size of the antibody chains produced.
  • the dose-dependent blockade activity of each of the recombinant antibodies to interfere with the interaction between LAG-3 and its recently discovered ligand fibrinogen-like protein 1 (FGL1) was assessed using ELISA in two different configurations as explained below.
  • First set of experiment involved coating the recombinant human LAG-3 (His tag) onto ELISA plates, followed by adding serially diluted concentrations of each anti-LAG-3 antibody preparation to bind to the coated LAG-3. Then a fixed amount of biotinylated FGL1 is added to be detected by HRP-conjugated streptavidin.
  • LAG-3 antibody upon binding to LAG-3, to block FGL1 interaction with LAG-3 is assessed by the amount of FGL1 bound to LAG-3 (FIG. 1. with IC50 shown in Table 2) .
  • Second set of experiments involved flipping the two analytes, LAG-3 and FGL1, where FGL1 is now coated onto the ELISA plates and assess how much of the LAG-3 bound by anti-LAG-3 antibody can bind to the immobilized FGL1. Analogously, serially diluted concentrations of each anti-LAG-3 antibody preparation was first bound to biotinylated LAG-3 and the complex was allowed to interact with the immobilized FGL1 on the ELISA plates.
  • the amount of LAG-3 was detected by HRP-conjugated streptavidin (FIG. 2. With IC50 shown in Table 2) .
  • the binding affinity of one of the anti-LAG-3 antibodies (SCT-Ca01) showing significant blockade activity in both configurations was measured on a surface plasmon resonance (SPR) instrument, such as a Biacore T200 TM , against human LAG-3.
  • SPR surface plasmon resonance
  • CDR complementarity-determining region
  • Baixeras E., Huard, B., Miossec, C., Jitsukawa, S., Martin, M., Hercend, T., Auffray, C., Triebel, F., and Piatier-Tonneau, D. (1992) . Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J. Exp. Med. 176, 327–337.
  • LAG-3 expression defines a subset of CD4 (+) CD25 (high) Foxp3 (+) regulatory T cells that are expanded at tumor sites. J. Immunol. Baltim. Md 1950 184, 6545–6551.
  • Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. Eur. J. Immunol. 24, 3216–3221.
  • LAP lymphocyte activation gene-3 (LAG-3) -associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3/TCR activation pathway. Eur. J. Immunol. 31, 2885–2891.
  • Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3. Cell 176, 334-347. e12.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des anticorps qui reconnaissent la protéine du gène d'activation des lymphocytes 3 (LAG -3).
PCT/CN2020/087141 2019-04-26 2020-04-27 Anticorps anti-lag -3 Ceased WO2020216383A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962839134P 2019-04-26 2019-04-26
US62/839,134 2019-04-26

Publications (1)

Publication Number Publication Date
WO2020216383A1 true WO2020216383A1 (fr) 2020-10-29

Family

ID=72941331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/087141 Ceased WO2020216383A1 (fr) 2019-04-26 2020-04-27 Anticorps anti-lag -3

Country Status (1)

Country Link
WO (1) WO2020216383A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016028672A1 (fr) * 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anticorps et fragments de fixation à l'antigène anti-lag3
WO2017015560A2 (fr) * 2015-07-22 2017-01-26 Sorrento Therapeutics, Inc. Anticorps thérapeutiques qui se lient à lag3
WO2017062888A1 (fr) * 2015-10-09 2017-04-13 Regeneron Pharmaceuticals, Inc. Anticorps anti-lag3 et leurs utilisations
WO2017087901A2 (fr) * 2015-11-19 2017-05-26 Sutro Biopharma, Inc. Anticorps anti-lag3, compositions comprenant des anticorps anti-lag3 et méthodes de production et d'utilisation d'anticorps anti-lag3
WO2018208868A1 (fr) * 2017-05-10 2018-11-15 Smet Pharmaceutical Inc Anticorps monoclonaux humains contre lag3 et leurs utilisations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016028672A1 (fr) * 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anticorps et fragments de fixation à l'antigène anti-lag3
WO2017015560A2 (fr) * 2015-07-22 2017-01-26 Sorrento Therapeutics, Inc. Anticorps thérapeutiques qui se lient à lag3
WO2017062888A1 (fr) * 2015-10-09 2017-04-13 Regeneron Pharmaceuticals, Inc. Anticorps anti-lag3 et leurs utilisations
WO2017087901A2 (fr) * 2015-11-19 2017-05-26 Sutro Biopharma, Inc. Anticorps anti-lag3, compositions comprenant des anticorps anti-lag3 et méthodes de production et d'utilisation d'anticorps anti-lag3
WO2018208868A1 (fr) * 2017-05-10 2018-11-15 Smet Pharmaceutical Inc Anticorps monoclonaux humains contre lag3 et leurs utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE Protein 2 April 2019 (2019-04-02), CHEN, Y. ET AL., XP055756513, retrieved from ncbi Database accession no. NP_002277 *

Similar Documents

Publication Publication Date Title
US20220332816A1 (en) Anti-tigit antibodies
TWI640536B (zh) 抗體
JP6974311B2 (ja) 新規ｐｄ−１免疫調節剤
CN110536903B (zh) 抗ox40抗体及其用途
JP2023055871A (ja) 抗ｎｋｇ２ａ抗体を使用した治療計画
US20230348584A1 (en) Use of anti-fam19a5 antibodies for treating cancers
WO2020238926A1 (fr) Anticorps anti-b7-h3
CN114651013B (zh) 对cd39具有特异性的结合分子及其用途
CN104024276A (zh) Lsr抗体及其用于癌症治疗的用途
JP2022512526A (ja) キノリン誘導体と抗体による薬物の組み合わせ
JP7308190B2 (ja) 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置
CN114599398A (zh) 用gm-csf拮抗剂治疗癌症
US20230279105A1 (en) Anti-tim-3 antibodies
US12116415B2 (en) Anti-BCMA antibodies
KR102693317B1 (ko) 암 면역요법을 위한, 활성화되고 확장된 자연 킬러 세포와 조합된 항-cxcr4 항체
WO2020216383A1 (fr) Anticorps anti-lag -3
Iizuka et al. Unstable B7-H4 cell surface expression and T-cell redirection as a means of cancer therapy
JP2022553643A (ja) 細胞傷害性ｔ細胞耐性腫瘍を治療するための組成物および方法
EP3617230A1 (fr) Nouvelles séquences d'anticorps et de nucléotides et utilisations associées
CN115845050A (zh) 抗-pd-1抗体及其在制备治疗食管鳞癌患者的药物中的用途
BR112018002824B1 (pt) Anticorpo isolado ou um fragmento de ligação, kit, usos do anticorpo e composição farmacêutica

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20794969

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20794969

Country of ref document: EP

Kind code of ref document: A1